Cellular Origins and Fresenius Kabi have signed a development agreement to integrate Fresenius Kabi’s cell therapy processing technologies with Cellular Origins’ CGT robotic manufacturing platform Constellation. The goal is to help cell therapy developers manufacture therapies at scale using preferred processing tools. The initial focus is on integrating Fresenius Kabi’s Cue Cell Processing System for fully automated manufacturing. The collaboration will expand to include Fresenius Kabi’s wider cell therapy technologies portfolio. Both companies believe that automation is essential for improving production efficiencies and reducing human errors in cell therapy manufacturing. They aim to advance the industry and benefit patients through automation.
Source link
Cellular Origins, Fresenius Kabi sign development agreement for scalable automation of cell and gene therapy manufacturing
